¡]¥»¤å§@ªÌ¬°°ê¥ß¬Fªv¤j¾Ç¬ì§ÞºÞ²z»P´¼¼z°]²£¬ã¨s©Ò°Æ±Ð±Â¡^
·ç¼w¦è³¡]Remdesivir¡A¤SºÙGS-5734¡^¸¹ºÙ¬OCOVID-19¯f¬rªº¸ÑÃÄ¡A³Ìªì¬O¬°¤FªvÀø¥ìªi©Ô¯f¬r¡]Ebolavirus¡^¦Ó¥Ñ¦N§Q¼w¬ì¾Ç¤½¥q¡]Gilead Sciences, Inc.¡^©Ò¶}µo¡CÃö©ó·ç¼w¦è³¡A¦N§Q¼w¦³µo©ú±M§Q¥Ó½Ð®×²Ä104135247¸¹¡uµ·ª¬¯f¬rÄݯf¬r·P¬V¤§ªvÀø¡v¡]¥Ó½Ð¤é¡G2015¦~10¤ë27¤é¡A¤½¶}¤é¬°2016¦~8¤ë16¤é¡^¡A¤w©ó2019¦~12¤ë20¤éªì¼f®Öã¼f©w¡A¨Ã©ó2020¦~2¤ë7¤é¥Ó½Ð»âÃÒ¡A¦Óµ¥«Ý¤½§i¤¤¡C¸Ó¥Ó½Ð®×¥Dn½Ð¨D¶µ¬°¤Æ¦Xª«½Ð¨D¶µ¡A¦Ó²Ä2¶µ§Y¬°·ç¼w¦è³ªº¤Æ¾Çµ²ºc¦¡¡C¤£¹L¡A¸Ó¥Ó½Ð®×¶ÈÄݩ󦳮Ħ¨¤À¤§·sÃÄ«~¡A¦Ó¥¼¯A¤Î¨ãÅ骺¡B¤@©w¾¯«¬¤Î¾¯¶qªº»s¾¯¡C¯S§O¬O¸Ó¥Ó½Ð®×¨Ã¥¼«üºÙ¥i¥HªvÀøCOVID-19¯f¬r¡C °²³]¥¼¨Ó¨ä¥L³æ¦ì¥H¡u·ç¼w¦è³¡v¬°°ò¦¨Óµo®iÃþ¦üªº¤Æ¦Xª«Q¡A¥H¥Î¨ÓªvÀøCOVID-19¯f¬r¡C¦pªG±N¸Ó¤Æ¦Xª«Q¥Ó½Ðµo©ú±M§Q®É¡A¥i¯à¦]²Ä104135247¸¹¥Ó½Ð®×¤º¸ê°T´¦ÅS¡A¨Ò¦p·ç¼w¦è³©Î¨ä¥L¬ÛÃöªº¤Æ¦Xª«¤§¤Æ¾Çµ²ºc¡B»s¾¯¦¨¤Àªº¦Cªíµ¥¡A¦Ó¦³·s¿o©Ê°ÝÃD¡C¹ï¦¹¡A¥»¤å«ØijÀ³¤Þ¤J¡m¼Ú¬w±M§Q±ø¬ù¡n²Ä54±ø²Ä4¶µ»P²Ä5¶µ¤§·s¿o©Ê³W©w¡A¥HÅý¡uÃþ¦ü©ó·ç¼w¦è³¡vªº¤Æ¦Xª«¦]¬°¯àªvÀøCOVID-19¯f¬r¦ÓÀò±o±M§QÅv«OÅ@¡C
¹Ï¤ù¨Ó·½¡GPixabay
·s¿o©Ê°ÝÃD
¦P¤@ÃÄ«~¥i¯à¦³¨âºØ¥H¤WªºÀø®Ä¡A¦ý³q±`©ó¥Ó½Ð±M§Q®É·|¶°¤¤¦b¤@ºØÀø®Ä¡A¦]¬°ÃÄ«~µo®i®É¶È·|°w¹ï³æ¤@¯e¯f¡C¤£¹L¡AÃÄ«~¸g¨Ï¥Î«á¥i¯àµo²{¦³²Ä¤GºØÀø®Ä¡A¨Ò¦p¡u«Â¦Ó¿û¡v쥻³]p©óªvÀø«aª¬°Ê¯ß¤ßŦ¯f¡A¦ý©ó¤HÅé¸ÕÅç´Á¤¤«oµo²{¨ä§ó¦³§Q©ó¨k©Ê«k°_¯à¤Oªººû«ù¡A¦Ó§ïÅܬ°ªvÀø¨k©Ê©Ê¥\¯à¯e¯f¡C
®Ú¾Ú±M§Q¼f¬d°ò·Ç¡A¦pªGÂåÃIJզXª«±M§Q¥Ó½Ð®×¤§¡u¨ã¦³¯S©w©Ê½èªº¤Æ¦Xª«¡v»P¡u¤ÞÃÒ¤å¥ó¤¤¤Æ¦Xª«¡v¬Û¦P¡A¥B¤GªÌ¤§®t²§¶È¬O¡u©Ò²£¥Í¤§ÂåÃĥγ~¤£¦P¡v®É¡A«h¸Ó±M§Q¥Ó½Ð®×¤§ÂåÃIJզ¨ª«¤D¤£¨ã·s¿o©Ê¡C¥ç§Y¡A°²³]¤@ÃÄ«~ªº²Ä¤@ºØÀø®Ä¬°¤wª¾¸ê°T¡A«h¨äµLªk¥H¦P¤@ÃÄ«~¦]²Ä¤GºØÀø®Ä¦Ó¥Ó½Ðª««~±M§Q¡C
Á|¨Ò¦Ó¨¥¡A¨tª§ÂåÃIJզXª«½Ð¨D¶µ¬°¡u¤@ºØ¥Î©óªvÀø¯e¯fZ¤§ÂåÃIJզ¨ª«¡A¨ä¥]§t¦³®Ä¶q¤§¤Æ¦Xª«A¡v¡A¦ý¤ÞÃÒ®×R´¦ÅS¡u¤@ºØ¥Î©óªvÀø¯e¯fX¤§ÂåÃIJզ¨ª«¡A¨ä¥]§t¦³®Ä¶q¤§¤Æ¦Xª«A¡v¦Ó¯e¯fZ¤£¦P©ó¯e¯fX¡A«h¦]¡u¤Æ¦Xª«A«Y¤wª¾ªº¡A¬G©Ò½ÐÂåÃIJզ¨ª«¤£¨ã·s¿o©Ê¡v¡C
¦¹·s¿o©Ê°ÝÃD¶È¯à¥H§ï¼g¬°ÂåÃĥγ~½Ð¨D¶µ¨Ó¤Æ¸Ñ¡C¡uÂåÃĥγ~½Ð¨D¶µ¡v¨ä»yªk¬°¡u¤Æ¦Xª«A¦b»s³ÆªvÀø¯e¯fX¤§ÃĪ«ªº¥Î³~¡v©Î¡uÂåÃIJզ¨ª«B¤§¥Î³~¡A¨ä«Y¥Î©ó»s³ÆªvÀø¯e¯fX¤§ÃĪ«¡vµ¥¼¶¼g§Î¦¡¡A¤SºÙ¬°¡u·ç¤h«¬½Ð¨D¶µ¡v¡]Swiss-type claim¡^¡A¹ê°È¤W¥Î¨Ó³B²zÃĪ«·s¥Î³~ªºµo©ú¡C®Ú¾Ú±M§Q¼f¬d°ò·Ç¡A¦pªG¡u¤@ºØ¥Î©óªvÀø¯e¯fZ¤§ÂåÃIJզ¨ª«¡A¨ä¥]§t¦³®Ä¶q¤§¤Æ¦Xª«A¡v×¥¿¬°¡u¤@ºØ¤Æ¦Xª«A¤§¥Î³~¡A¨ä«Y¥Î©ó»s³ÆªvÀø¯e¯fZ¤§ÂåÃIJզ¨ª«¡v¡A«h¨ä¬Û¸û©ó«ez¤ÞÃÒ®×R§Y¨ã·s¿o©Ê¡C
¦¹·s¿o©Ê¤§¦Ò¶qÁö¤£§Q©ó²Ä¤G¥Î³~ÂåÃÄ«~¥Hª««~±M§Q«OÅ@¡A¦ý¨ä²Å¦X±M§Q¼f¬d°ò·Çªº¤º¦bÅÞ¿è¤@P©Ê¡C¨Ò¦p¡u¥H»sªk¬É©wª«¤§½Ð¨D¶µ¡v¤D¥H¡u»s³Æ¨BÆJ¤Î°Ñ¼Æ±ø¥óµ¥«n§Þ³N¯S¼x¡v¨Ó¬É©wª««~½Ð¨D¶µ¡C±M§Q¼f¬d°ò·Ç«ü¥X¸ÓÃþ½Ð¨D¶µ¡u¨ä¬O§_¨ã³Æ·s¿o©Ê©Î¶i¨B©Ê¨Ã«D¥Ñ»sªk¨M©w¡A¦Ó«Y¥Ñ¸Óª«¥»¨¨Ó¨M©w¡v¡C¦]¦¹¡A¡u§Y¨Ï¥ý«e§Þ³N©Ò´¦ÅS¤§ª««Y¥H¤£¦P¤èªk©Ò»s±o¡v¡A¤@¥¹¸Ó¤w´¦ÅS¤§ª«»P¥»¥Ó½Ð®×¤§ª«¬Û¦P©ÎÄݯ໴©ö§¹¦¨ªÌ¡A«h¥»¥Ó½Ð®×¤§ª««~½Ð¨D¶µ¤´¤£±o¤©¥H±M§Q¡C¥t¤è±¡AÃö©ó¥H²Ä¤G¥Î³~¬°¯S¼xªºÃÄ«~½Ð¨D¶µ¡A¨ä¯S¼xÁö¬O¸Ó²Ä¤G¥Î³~¡A¦ý¸Ó½Ð¨D¶µ¥»½è¤´¬Oª««~½Ð¨D¶µ¡A¬G·s¿o©Ê©Î¶i¨B©Ê¤§§PÂ_¤´¥H¸ÓÃÄ«~¥»¨¬°¥D¡C
ÂåÃĥγ~½Ð¨D¶µ¤§°ÝÃD
¡uÂåÃĥγ~½Ð¨D¶µ¡v°ò¥»¤W¦b´£¨Ñ²Ä¤G¥Î³~ÂåÃÄ«~¤§«OÅ@¡A¦ý°ò¥»¤º®e¶È¬O³¯zÂåÃĪ««~¥\¯à¡]§Y¡u¨ä«Y¥Î¥H»s³Æ ¡K¡v¡^¡A¨äµLºc¥ó©Î¨BÆJªº¤º®e¡A¬G¾ÉP¨ä¥»½è¬Oª««~©Î¤èªkªº¤£©ú½T°ÝÃD¡C¤SÁö¥i¥[¤WÂåÀø¨BÆJªº§Þ³N¯S¼x¡A¦ý¦]¨ä¡u¥Î¥H»s³Æ¡v¥Î»y¦Ó¤£³Qµø¬°¤èªk½Ð¨D¶µ¡Fªp¥B¡AY³Qµø¬°¤èªk½Ð¨D¶µ¡A«h·|¸¨¤J¤£¤©±M§Qªº¼Ð¡]§YªvÀø¤èªk¡^ªº½dÃ¥¡C
±M§Q¼f¬d°ò·Ç«ü¥X¦³¤TÃþ½Ð¨D¶µÄÝ©ó¡u½dÃ¥¤£©ú½T¡v¡A¥]¬A¡]1¡^µo©ú½dÃ¥¤£©ú½T¡A¨Ò¦p¡u¤@ºØ¤èªk©Î¸Ë¸m¡v©Î¡u¤@ºØ¤èªk¤Î¸Ë¸m¡v¡F¡]2¡^µLªk§PÂ_½Ð¨D¶µ©Ò«üªÌ¬°ª«©Î¤èªk¡A¨Ò¦p¡u¤@ºØª«½èXªºY¥\®Ä¡v¡F¡]3¡^½Ð¨D¶µ¤Þ¥Î¤GºØ¥H¤W¤§½dÃ¥¡A¨Ò¦p¡u¦p½Ð¨D¶µ1¤§ª«½èX©Î½Ð¨D¶µ2¤§ª«½èY¡v¡C¦¹¤TÃþ¤£©ú½T°ÝÃD¬Ò·½¦Û©ó½Ð¨D¶µ¥»¨µLªk¬É©w¬°ª««~©Î¤èªk¡C
¥t³Ì°ªªk°|´¿©ó104¦~«×¥x¤W¦r²Ä1485¸¹¥Á¨Æ§P¨M¤¤¡An¨D´¼°]ªk°|À³¼f¬d¨tª§½Ð¨D¶µ¨ä¤£©ú½Tì¦]¬O§_¡u«Y¦]µLªk©ú½T¬É©w¨s«Yª«¤§µo©ú©Î¤èªkµo©ú¡v©ÒP¡CÅã¥Ü½Ð¨D¶µªº©ú½T©Ê¡A¬O°ò©ó¨ä¯à§_³Q¬É©w¬°ª««~©Î¤èªk¦Ó©w¡C
Áö±M§Q¼f¬d°ò·ÇµøÂåÃĥγ~½Ð¨D¶µ¬°¡u¤@ºØ»s³ÆÃĪ«¤§¤èªk¡v¡A¦ý»s³ÆÃĪ«¤§¤èªk¦³¨ä¿W¥ßªº½Ð¨D¶µ»yªk¡A¨Ò¦p¡u¤@ºØÂåÃIJզ¨ª«¤§»s³Æ¤èªk¡v¡C
¤S®Ú¾Ú±M§Q¼f¬d°ò·Ç¡A¹ê¬I¤è¦¡ªº°O¸ü¤º®e¡u¹ï©ó¤èªkµo©ú¡AÀ³±Ô©ú¨ä¨BÆJ¡A±o¥H¤£¦Pªº°Ñ¼Æ©Î°Ñ¼Æ½d³òªí¥Ü¨ä§Þ³N±ø¥ó¡v¡CÁö±M§Q¼f¬d°ò·Ç©Î±M§Qªk¬I¦æ²Ó«h¥¼©úq¤èªk½Ð¨D¶µªº¨ãÅ餺®e¡A¦ýn¨D¤èªkµo©úªº¹ê¬I¨ÒÀ³°O¸ü¸Ó¤èªk¤§¨BÆJ¤º®e¡A¦¹·N²[¡u¨BÆJ¡v¤D¤èªkµo©ú¤§§Þ³N¯S¼x¡A¬G¦ÛµMÀ³¬°¬ÛÃö¤èªk½Ð¨D¶µ¤§§Þ³N¯S¼x¡C
¬JµMµøÂåÃĥγ~½Ð¨D¶µ¬°»s³ÆÃĪ«¤§¤èªk¡A«h¸ÓÂåÃĥγ~½Ð¨D¶µ¤ºÀ³¦³»s³ÆÃĪ«¤§¬ÛÃö¨BÆJ¡CµM¦Ó¡AÂåÃĥγ~½Ð¨D¶µ¤ºªº§Þ³N¯S¼xµÛ«©ó¡uÃÄ«~ªº¨Ï¥Î¡v©Î¡uÃÄ«~ªº¦¨¤À¡v¡F«eªÌÄݨBÆJ¦ý«D»s³ÆÃĪ«¤§¨BÆJ¡A¦Ó«áªÌÄݪ««~¤§§Þ³N¯S¼x¡A¥B¤GªÌ³£µLªk´yzÃĪ«»s³Æ¡C¦]¦¹¡Aµø¡uÂåÃĥγ~½Ð¨D¶µ¡v¬°¡u¤@ºØ»s³ÆÃĪ«¤§¤èªk¡v¤D§ó¹üÅã¸ÓÃþ½Ð¨D¶µªº¤£©ú½T°ÝÃD¡C
¡m¼Ú¬w±M§Q±ø¬ù¡n²Ä54±ø¤§ÉÃè
¦b104¦~«×¥x¤W¦r²Ä1485¸¹¥Á¨Æ§P¨M¤¤¡A³Ì°ªªk°|«ü³d´¼°]ªk°|¡u¥¼»¡©ú¬ÛÃöªk³W¤§©Ò¨Ì¾Ì¡v¡A¦Ó³w¦æ»{©w¨tª§¤èªk½Ð¨D¶µ¤§¤º®e¬°¤£¯àªí¹F¤èªkµo©ú¤§§Þ³N¯S¼x¡C¦¹·N²[·í½Ð¨D¶µªº¼¶¼g²Å¦X´¼°]§½ªºªk³W®É¡A¸Ó½Ð¨D¶µ§Y¬°¦Xªk¡C
µM¦Ó¡A¬°ÁקK«ez©ú½T©Ê¤§ºÃ¼{¡A¥»¤å«Øij¥xÆW±M§Qªkªº·s¿o©Ê³W©w¥i¤Þ¤J¡m¼Ú¬w±M§Q±ø¬ù¡n²Ä54±ø²Ä4¶µ»P²Ä5¶µªº¥ßªk¼Ò¦¡¡A¥Hã³\ÃÄ«~½Ð¨D¶µ¥H·s¿oªºÀø®Ä¨Ó¨ú±o±M§Q¡C
¡m¼Ú¬w±M§Q±ø¬ù¡n²Ä54±ø³W½d·s¿o©Êªºn¥ó¡A¦@¦³¤¶µ¡C²Ä1¶µ«ü¥X¡u¤@¥óµo©úÀ³³Qµø¬°·s¿oªº¡A¦pªG¨ä¨Ã¥¼ºc¦¨²{¦³§ÞÃÀªº¤@³¡¤À¡v¡C²Ä2¶µ©w¸q¡u²{¦³§ÞÃÀÀ³¥]¬A©ó¼Ú¬w±M§Q¥Ó½Ð¤é¤§«e¤w¤½½Ñ©ó¤j²³ªº©Ò¦³¨Æª«¡A¦Ó¤½½Ñ¤è¦¡¬°®Ñ±©Î¤fzªº¸ÑÄÀ¡B¨Ï¥Î¡B©Î¨ä¥L¤èªk¡v¡C²Ä3¶µ±N¡u²{¦³§ÞÃÀ¡v©µ¦ù¦Ü¤w¸g¥Ó½Ðªº¡B¦ý¦b²Ä2¶µ©Ò«ü¤§¥Ó½Ð¤é·í¤é©Î¤§«á¤~¤½¶}ªº¼Ú¬w±M§Q¥Ó½Ð®×¡C
²Ä4¶µ©M²Ä5¶µ°w¹ïÂåÀø¥Î³~¤§¡uª«½è¡v¡]substance¡^©Î¡u²Õ¦Xª«¡v¡]composition¡^ªº·s¿o©Ê°µ¯S§O³W©w¡C²Ä4¶µ³W©w²Ä2¶µ©Î²Ä3¶µ©Ò²[»\ªº²{¦³§ÞÃÀ¤£¥i¥Î©ó§_©wª«½è©Î²Õ¦Xª«¤§·s¿o©Ê¡A¦pªG¸Óª«½è©Î²Õ¦Xª«©Ò¯A¤ÎªºÂåÀø¦æ¬°¥Î³~«DÄÝ©ó²{¦³§ÞÃÀ¡C¶i¤@¨B¡A²Ä5¶µ³W©w´N²Ä4¶µ©Ò«ü¤§ª«½è©Î²Õ¦Xª«¡A¨ä·s¿o©Ê¤£±o¥H²Ä2¶µ©Î²Ä3¶µ©Ò²[»\ªº²{¦³§ÞÃÀ¤©¥H§_©w¡A¦pªG¸Óª«½è©Î²Õ¦Xª«©óÂåÀø¦æ¬°®É©Ò´£¨Ñ¤§¯S©w¨Ï¥Î«DÄݲ{¦³§ÞÃÀ¡C
¦b¡m¼Ú¬w±M§Q±ø¬ù¡n²Ä54±ø²Ä4¶µ»P²Ä5¶µªº¬[ºc¤U¡A¦P¤@ÃÄ«~¥i¦]¬°¦³·s¿oªºÂåÀø¥Î³~¦Ó¦P¼Ë¥HÃÄ«~½Ð¨D¶µ¨ú±o·sªº±M§Q«OÅ@¡C¬Æ¦Ü¡A¼Ú¬w±M§Q§½©ó¨ä¼f¬d°ò·Ç¤¤«ü¥X¹ï©ó¤wª¾ªºª«½è©Î²Õ¦Xª«¡AY¨äº¦¸§Q¥Î©óÂåÀø¦æ¬°®É¡A¸Óª«½è©Î²Õ¦Xª«¥i°ò©ó²Ä54±ø²Ä4¶µ¦Ó¨ú±o·s¿o©Ê¡C
¼Ú¬w±M§Q§½¼f¬d°ò·Ç¥ç´£¥X¾A·íªº½Ð¨D¶µ¼gªk¡A§Y¡uª«½èX¡A¨ä©ó¯e¯fYªºªvÀø¤¤¨Ï¥Î¡v¡]Substance X for use in the treatment of disease Y¡^¡B©Î¡uª««~X¡A¨ä°µ¬°ÃÄ«~¤§¨Ï¥Î¡v¡]Product X for use as a medicament¡^¡C¥²nªº¥Î»y¬O¡u¥Î¥H¡v¡]for use¡^¡A¥H¨ú±o²Ä54±ø²Ä4¶µ»P²Ä5¶µ©Òµ¹¤©ªº·s¿o©ÊÁŧK¡C
¦¹¥~¡A¡u©ó¯e¯fYªºªvÀø¤¤¡v¡]in the treatment of disease Y¡^¤§¥Î»y¦³¨äÅܧΪº¿ï¾Ü¡A¨Ò¦p¡G¡u©óªvÀø¯e¯fYªº¤èªk¤¤¡v¡]in a method for the treatment of Y¡^¡B¡u©óYªºÀøµ{¤¤¡v¡]in the therapy of Y¡^¡B¡u©óªvÀøYªº¤èªk¤¤¡v¡]in a method of treating Y¡^¡B¡u©óYÀøµ{¤§¤èªk¤¤¡v¡]in a method of therapy of Y¡^µ¥µ¥¡C¥t´N¡u¨ä°µ¬°ÃÄ«~¡v¡]as a medicament¡^¤§¥Î»y¡A¦p½Ð¨D²Ä¤GÂåÀø¥Î³~¤§«OÅ@¡A¡uÃÄ«~¡vªº¥Î»y¥²¶·¨ãÅé¨ì¯S©wÀø®Ä¤§ÃÄ«~¡A¨Ò¦p¡G¡u¨ä°µ¬°®øª¢ÃÄ«~¡v¡] as an anti-inflammatory medicament¡^¡C
תk¤§«Øij
¥Ø«e¡A¥xÆW±M§Qªk°t®M±M§Q³sµ²¨î«×ªº×ªk¤´¶i¦æ¤¤¡C¦b¦¹¨è¡A¤Þ¤J¼Ú¬w±M§Q¤§¹ê°È¡A¶}©ñ¥Hª««~½Ð¨D¶µªº§Î¦¡¨Ó«OÅ@ÃÄ«~ªºÂåÀø¥Î³~¡A¦ý¤´¥iºÙ¨ä¬°¡uÂåÃĥγ~½Ð¨D¶µ¡v¡C¦p¦¹¤@¨Ó¡A¥i³B²z¶Ç²Î¡uÂåÃĥγ~¡vÃþªº±M§Qªº¤£©ú½Tªº°ÝÃD¡A¥H¥¿±`µo´§±M§Q³sµ²¨î«×ªº¥\¯à¡C